Sinha R, Ahsan H, Blaser M, et al. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017. Microbiome. 2018;6(1):210. doi:10.1186/s40168-018-0596-z.

Singh G, Dahlin JL, Walters MA. Risk Management in Early Discovery Medicinal Chemistry. Methods Enzymol. 2018;610:1-25. doi:10.1016/bs.mie.2018.09.012.

Bagheri N, Carpenter AE, Lundberg E, Plant AL, Horwitz R. The new era of quantitative cell imaging-challenges and opportunities. Mol Cell. 2022;82(2):241-247. doi:10.1016/j.molcel.2021.12.024.

Gupta-Ostermann D, Wawer M, Wassermann AM, Bajorath J. Graph mining for SAR transfer series. J Chem Inf Model. 2012;52(4):935-42. doi:10.1021/ci300071y.

Sinha R, Abu-Ali G, Vogtmann E, et al. Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium. Nat Biotechnol. 2017;35(11):1077-1086. doi:10.1038/nbt.3981.

Marder SR, Roth B, Sullivan PF, et al. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci. 2011;1236:30-43. doi:10.1111/j.1749-6632.2011.06216.x.

Mahlman M, Karjalainen MK, Huusko JM, et al. Genome-wide association study of bronchopulmonary dysplasia: a potential role for variants near the CRP gene. Sci Rep. 2017;7(1):9271. doi:10.1038/s41598-017-08977-w.

Mallick H, Ma S, Franzosa EA, Vatanen T, Morgan XC, Huttenhower C. Experimental design and quantitative analysis of microbial community multiomics. Genome Biol. 2017;18(1):228. doi:10.1186/s13059-017-1359-z.

Ma Y, De Jager PL. Designing an epigenomic study. Mult Scler. 2018;24(5):604-609. doi:10.1177/1352458517750770.

Renfro LA, Mallick H, An M-W, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev. 2016;43:74-82. doi:10.1016/j.ctrv.2015.12.008.